Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance
February 27, 2019 7:00 AM EST
-- Fourth-Quarter 2018 Net Sales Increased 30 Percent to $355.5
Million Driven by 33 Percent Growth in Orphan and Rheumatology Segment;
Fourth-Quarter
2018 GAAP Net Income of $87.6 Million; Adjusted EBITDA of $151.1 Million
--
-- Full-Year 2018 Net Sales Increased 14 Percent to $1.21 Billion
Driven by 22 Percent Growth in Orphan and Rheumatology Segment;
Full-Year
2018 GAAP Net Loss of $74.2 Million; Adjusted EBITDA of $451.4 Million --
-- Full-Year Orphan and Rheumatology Segment Net Sales of $831.5
Million
Representing Approximately 70 Percent of Total
Company Full Year Net Sales;
Segment Operating Income of
$290.0 Million --... More
